Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases
Sijie Zhou, Yuan Li, Jiulu Zhao, Wang Zhan, Cheng Zhou, Yanqiang Zou, Xiaohan Li, Jikai Cui, Jie Wu, Jiahong Xia · 2026
Read Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases by Sijie Zhou, Yuan Li, Jiulu Zhao, Wang Zhan, Cheng Zhou, Yanqiang Zou, Xiaohan Li, Jikai Cui, Jie Wu, Jiahong Xia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272466.txt.
Description
Sijie Zhou and coauthors survey in 2026 how chimeric antigen receptor cell therapy, first built for cancer, is being reshaped for diseases that are not cancer. The method rebuilds a patient's immune cells so they hunt one chosen target with great precision. That precision can serve autoimmune, infectious, and scarring diseases as well.
One path uses the rebuilt cells to wipe out the exact cell groups that drive disease. The other path installs rebuilt guard cells that calm immune attack, with promise for organ transplants, bowel inflammation, and type 1 diabetes. How long the cells last, how safe they are, and how hard they are to make remain the shared hurdles.
Catalog record
| CREATOR | Sijie Zhou, Yuan Li, Jiulu Zhao, Wang Zhan, Cheng Zhou, Yanqiang Zou, Xiaohan Li, Jikai Cui, Jie Wu, Jiahong Xia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |